ClinicalTrials.Veeva

Menu
T

The Centre for Clinical Trials | Oakvile, Canada

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

CTP-543
PF-06651600
Rocatinlimab
Rezpeg
Rezpegaldesleukin
BI 730357
AMG 451
Upadacitinib
TP-04
AGN-151586

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

12 of 25 total trials

A 104-Week Study of Ritlecitinib Oral Capsules in Adults With Nonsegmental Vitiligo (Active and Stable) Tranquillo 2

The purpose of this study is to learn about the safety and effects of the study medicine ritlecitinib for the possible treatment of nonsegmental viti...

Enrolling
Stable Nonsegmental Vitiligo
Active Nonsegmental Vitiligo
Drug: Ritlecitinib
Drug: Placebo

This is an interventional, randomized, parallel group, treatment, Phase IIb, double blind, 4-arm study to assess the effect of pegylated-recombinant-...

Enrolling
Moderate to Severe Atopic Dermatitis
Drug: Rezpegaldesleukin
Drug: Placebo

This is an interventional, randomized, double blind, parallel group, placebo-controlled, Phase 2b, 3-arm study to assess the effect of pegylated-reco...

Enrolling
Alopecia Areata
Drug: Rezpegaldesleukin
Drug: Placebo

The co-primary objectives of the study are to:* Evaluate the efficacy of rocatinlimab compared with placebo at Week 24, assessed using Validated Inve...

Active, not recruiting
Atopic Dermatitis
Other: Placebo
Drug: Rocatinlimab

The cumulative effect of aging and environmental exposures (ie, ultraviolet, infrared, and visible light radiation and pollution) leads to wrinkles,...

Active, not recruiting
Mid Face Volume Deficit
Device: HArmonyCa Lidocaine Injectable Gel
Locations recently updated

The primary objective of this study is to describe the long-term safety and tolerability of rocatinlimab in participants with moderate-to-severe AD.

Enrolling
Atopic Dermatitis
Drug: Rocatinlimab
Other: Placebo

The objective of this study is to assess the efficacy and safety of upadacitinib combined with topical corticosteroids (TCS) for the treatment of ado...

Invitation-only
Atopic Dermatitis
Drug: Placebo
Drug: Upadacitinib

Visit the study website https://dawnacnescarstudy.com/ACT for more information. Atrophic acne scars are flat, indented or with an inverted center sca...

Enrolling
Atrophic Acne Scars
Device: ELAPR002f Injectable Gel
Other: Saline Control

The overall objectives of the study are to evaluate long-term safety of CTP-543 and to assess long-term effects of CTP-543 on treating hair loss in a...

Active, not recruiting
Alopecia Areata
Drug: CTP-543

This is a global Phase 3 study to evaluate the safety and effectiveness of an investigational study drug (called PF-06651600) in adults and adolescen...

Active, not recruiting
Alopecia Areata
Biological: Meningococcal (groups A, C, W-135 and Y [ACWY]) oligosaccharide diphtheria CRM197 conjugate vaccine
Biological: Tetanus and diphtheria toxoids and acellular pertussis (Tdap) vaccine

This is designed to assess the long-term safety and efficacy of lebrikizumab for moderate-to-severe atopic dermatitis. It will last up to 33 months.

Active, not recruiting
Atopic Dermatitis
Biological: Lebrikizumab

B7451015 is a Phase 3 study to evaluate Abrocitinib with or without Topical Medications in patients aged 12 years and older who have moderate to seve...

Active, not recruiting
Dermatitis, Atopic
Drug: Abrocitinib 200 mg
Drug: Abrocitinib 100 mg

Trial sponsors

Pfizer logo
AbbVie logo
Amgen logo
Concert Pharmaceuticals logo
Allergan logo
Boehringer Ingelheim logo
Lilly logo
Nektar Therapeutics logo
P
Tarsus Pharmaceuticals logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems